![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Ontario Clinical Oncology Group (OCOG) |
---|---|
Information provided by: | Ontario Clinical Oncology Group (OCOG) |
ClinicalTrials.gov Identifier: | NCT00548600 |
The specific objective of this study is to compare the relative efficacy of the combination of a temporary iridium implant plus external beam irradiation versus standard external beam irradiation alone in patients with Stage B2 and C prostatic carcinoma. Benefit will be assessed in terms of local recurrence, survival, and toxicity.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Procedure: Iridium Implant Radiation: Standard external beam irradiation |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Clinical Trial Comparing Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy Using a Combination of a Temporaory Iridium Implant Plus External Beam Radiation in Surgically Staged B2 and C Carcinoma of the Prostate |
Enrollment: | 112 |
Study Start Date: | May 1992 |
Study Completion Date: | September 2006 |
Arms | Assigned Interventions |
---|---|
1: Experimental
Iridium implant plus external beam irradiation
|
Procedure: Iridium Implant
Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
|
2: Active Comparator
Standard external beam irradiation alone
|
Radiation: Standard external beam irradiation
Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
|
Ages Eligible for Study: | up to 75 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | OCOG-1992-Iridium |
Study First Received: | October 22, 2007 |
Last Updated: | October 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00548600 History of Changes |
Health Authority: | Canada: Health Canada |
Prostate Cancer Iridium Implant Radiotherapy |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Genital Diseases, Male Prostatic Neoplasms Carcinoma |
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |